Short-term CPAP treatment induces a mild increase in inflammatory cells in patients with sleep apnoea syndrome

Rhinology

Volumn 46, Issue 2, 2008, Pages 144-150

  Skoczyński, Szymon ^a   Ograbek Król, Mariola ^a   Tazbirek, Maciej ^a   Semik Orzech, Aleksandra ^a   Pierzchała, Władysław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

CPAP; Nasal lavage; Rhinomanometry; SAS

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; NOSE MUCUS; PATHOLOGY; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOMANOMETRY; SLEEP APNEA SYNDROME; TIME; TREATMENT REFUSAL;

ADULT; AGED; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; PATIENT COMPLIANCE; RHINITIS; RHINOMANOMETRY; SEVERITY OF ILLNESS INDEX; SLEEP APNEA SYNDROMES; TIME FACTORS; TREATMENT REFUSAL;

EID: 44849090892     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force Sleep 1999 1; 22: 667-689.
2. McNicholas WT, Bonsigore MR, Management Committee of EU COST ACTION B26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156-178.
3. Kramer MF, de la Chaux R, Fintelmann R, Rasp G. NARES: a risk factor for obstructive sleep apnoea? Am J Otolaryngol 2004; 25: 173-177.
4. Rubinstein I. Nasal inflammation in patients with obstructive sleep apnoea. Laryngoscope 1995; 105: 175-177.
5. Staevska MT, Mandajieva MA, Dimitrov VD. Rhinitis and sleep apnoea. Curr Allergy Asthma Rep 2004; 4: 193-199.
6. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intimamedia thickness and serum inflammatory markers in obstructive sleep apnoca. Am J Respir Crit Care Med 2005 1; 172: 625-630.
7. Kiely JL, Nolan P, McNicholas WT. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004; 59: 50-55.
8. Stradling JR, Crosby JH. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax 1991; 46: 85-90.
9. Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997; 99: 757-762.
10. Virkkula P, Maasilta P, Hytonen M, Salmi T, Malmberg H. Nasal obstruction and sleep-disordered breathing: the effect of supine body position on nasal measurements in snorers. Acta Otolaryngol 2003; 123: 648-654.
11. Li HY, Wang PC, Hsu CY, Cheng ML, Liou CC, Chen NH. Nasal resistance in patients with obstructive sleep apnoea. ORL J Otorhinolaryngol Relat Spec 2005; 67: 70-74.
12. McLean HA, Urton AM, Driver HS, et al. Effect of treating severe nasal obstruction on the severity of obstructive sleep apnoea. Eur Respir J 2005; 25: 521-527.
13. Bossi R, Piatti G, Roma E, Ambrosetti U. Effects of long-term nasal continuous positive airway pressure therapy on morphology, function, and mucociliary clearance of nasal epithelium in patients with obstructive sleep apnoea. syndrome. Laryrigoscope 2004; 114: 1431-1434.
14. Hayes MJ, McGregor FB, Roberts DN, Schroter RC, Pride NB. Continuous nasal positive airway pressure with a mouth leak: effect on nasal mucosal blood flux and nasal geometry. Thorax 1995; 50: 1179-1182.
15. Nandwani N, Caranza R, Hanning CD. Obstructive sleep apnoea and upper airway reactivity. J Sleep Res 1998; 7: 115-118.
16. Olopade CO, Christon JA, Zakkar M, et al. Exhaled pentane and nitric oxide levels in patients with obstructive sleep apnoea. Chest 1997; 111: 1500-1504.
17. Desfonds P, Planes C, Fuhrman C, Foucher A, Raffestin B. Nasal resistance in snorers with or without sleep apnoea: effect of posture and nasal ventilation with continuous positive airway pressure. Sleep 1998; 15: 625-632.
18. Massie CA, Hart RW, Peralez K, Richards GN. Effects of humidification on nasal symptoms and compliance in sleep apnoea patients using continuous positive airway pressure. Chest 1999; 116: 403-408.
19. Ballester E, Solans M, Vila X, et al. Evaluation of a portable respiratory recording device for detecting apnoeas and hypopnoeas in subjects from a general population. Eur Respir J 2000, 16: 123-127.
20. Clement PA, Gordts F; Standardisation Committee on Objective Assessment of the Nasal Airway, IRS, and ERS. Consensus report on acoustic rhinometry and rhinomanometry. Rhinology 2005; 43: 169-179.
21. Greiff L, Pipkorn U, Alkner U, Persson CG. The 'nasal pool' device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions.Clin Exp Allergy. 1990; 20: 253-259.
22. Ballester E, Badia JR, Hernandez L, et al. Evidence of the effectiveness of continuous positive airway pressure in the treatment of sleep apnoea/ hypopnoea syndrome. Am J Respir Crit Care Med 1999; 159: 495-501.
23. Hudgel DW. The role of upper airway anatomy and physiology in obstructive sleep apnoea. Clin Chest Med 1992; 13: 383-398.
24. Brander PE, Soirinsuo M, Lohela P. Nasopharyngeal symptoms in patients with obstructive sleep apnoea syndrome. Effect of nasal CPAP treatment. Respiration 1999; 66: 128-135.
25. Lowe AA, Fleetham JA, Adachi S, Ryan CF. Cephalometric and computed tomographic predictors of obstructive sleep apnoea severity. Am J Orthod Dentofacial Orthop 1995; 107: 589-595.
26. Sugiura T, Noda A, Nakata S, et al. Influence of nasal resistance on initial acceptance of continuous positive airway pressure in treatment for obstructive sleep apnoea syndrome. Respiration 2007; 74: 56-60.
27. Minoguchi Y, Yokoe T, Tazaki T, Minoguchi H, Tanaka A, Oda N, Okada S, Ohta S, Naito H, Adachi M. Increased carotid intimamedia thickness and serum inflammatory markers in obstructive sleep apnoea. Am J Respir Crit Care Med 2005; 172: 625-630.
28. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnoea after night and is reduced by continuous positive airway pressure therapy. Chest 2003; 124: 1386-1392.
29. Li AM, Hung E, Tsang T, et al. Induced sputum inflammatory measures correlate with disease severity in children with obstructive sleep apnoea. Thorax 2007; 62: 75-79.
30. Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D. Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnoea syndrome. Chest 2006; 130: 143-148.
31. Devouassoux G, Levy P, Rossini E, et al. Sleep apnoea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol 2007; 119: 597-603.
32. Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnoea syndrome pathogenesis: a working hypothesis. Respiration 2003; 70: 665-671.